IGF2BP1与肿瘤

doi:10.3760/cma.j.cn371439-20200923-00017

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (2): 92-95.doi: 10.3760/cma.j.cn371439-20200923-00017

IGF2BP1与肿瘤

何哲锋, 裴铁民, 孟庆辉()

哈尔滨医科大学附属第一医院肛肠外科 150001

收稿日期:2020-09-23 修回日期:2020-10-07 出版日期:2021-02-08 发布日期:2021-03-11
通讯作者: 孟庆辉 E-mail:hui-90@163.com
基金资助:
国家自然科学基金(81602050)

IGF2BP1 and cancer

He Zhefeng, Pei Tiemin, Meng Qinghui()

Department of Anorectal Surgery, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

Received:2020-09-23 Revised:2020-10-07 Online:2021-02-08 Published:2021-03-11
Contact: Meng Qinghui E-mail:hui-90@163.com
Supported by:
National Natural Science Foundation of China(81602050)

摘要/Abstract

摘要：

胰岛素样生长因子2 mRNA结合蛋白1(IGF2BP1)是机体发育过程中mRNA代谢和转运的关键调控因子。近年来研究发现,IGF2BP1在肝癌、肺癌、结肠癌、卵巢癌、乳腺癌等多种肿瘤中异常表达。IGF2BP1不仅与肿瘤细胞的增殖、迁移和侵袭有关,而且还与患者不良预后密切相关。进一步研究IGF2BP1在恶性肿瘤中的作用机制有望为肿瘤靶向治疗提供新的方法。

关键词: 肿瘤, RNA,信使, 分子靶向治疗, 胰岛素样生长因子2 mRNA结合蛋白1

Abstract:

The insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is a key regulator of mRNA metabolism and transport during development. Recent studies indicate that IGF2BP1 is aberrantly expressed in liver cancer, lung cancer, colon cancer, ovarion cancer, breast cancer, etc.. IGF2BP1 expression is found to promote tumor cell proliferation, migration, invasion, and correlate with poor prognosis. Further understanding of the mechanism of IGF2BP1 in malignancy may provide new targeted therapy strategies.

Key words: Neoplasms, RNA, messenger, Molecular targeted therapy, Insulin-like growth factor 2 mRNA-binding protein 1

何哲锋, 裴铁民, 孟庆辉. IGF2BP1与肿瘤[J]. 国际肿瘤学杂志, 2021, 48(2): 92-95.

He Zhefeng, Pei Tiemin, Meng Qinghui. IGF2BP1 and cancer[J]. Journal of International Oncology, 2021, 48(2): 92-95.

参考文献 12

[1]	Bell JL, Wächter K, Mühleck B, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?[J]. Cell Mol Life Sci, 2013,70(15):2657-2675. DOI: 10.1007/s00018-012-1186-z. doi: 10.1007/s00018-012-1186-z
[2]	Carmel MS, Kahane N, Oberman F, et al. A novel role for VICKZ proteins in maintaining epithelial integrity during embryogenesis[J]. PLoS One, 2015,10(8):e0136408. DOI: 10.1371/journal.pone.0136408. doi: 10.1371/journal.pone.0136408
[3]	Huang H, Weng H, Sun W, et al. Recognition of RNA N6-methyla-denosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat Cell Biol, 2018,20(3):285-295. DOI: 10.1038/s41556-018-0045-z. doi: 10.1038/s41556-018-0045-z
[4]	Biswas J, Nunez L, Das S, et al. Zipcode binding protein 1 (ZBP1; IGF2BP1): a model for sequence-specific RNA regulation[J]. Cold Spring Harb Symp Quant Biol, 2019,84:1-10. DOI: 10.1101/sqb.2019.84.039396. doi: 10.1101/sqb.2019.84.039396 pmid: 32086331
[5]	Gutschner T, Hämmerle M, Pazaitis N, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma[J]. Hepatology, 2014,59(5):1900-1911. DOI: 10.1002/hep.26997. doi: 10.1002/hep.26997
[6]	Yuan P, Meng L, Wang N. SOX12 upregulation is associated with metastasis of hepatocellular carcinoma and increases CDK4 and IGF2BP1 expression[J]. Eur Rev Med Pharmacol Sci, 2017,21(17):3821-3826. pmid: 28975985
[7]	Peng L, Yuan XQ, Zhang CY, et al. The emergence of long non-coding RNAs in hepatocellular carcinoma: an update[J]. J Cancer, 2018,9(14):2549-2558. DOI: 10.7150/jca.24560. doi: 10.7150/jca.24560 pmid: 30026854
[8]	Xu Y, Zheng Y, Liu H, et al. Modulation of IGF2BP1 by long non-coding RNA HCG11 suppresses apoptosis of hepatocellular carcinoma cells via MAPK signaling transduction[J]. Int J Oncol, 2017,51(3):791-800. DOI: 10.3892/ijo.2017.4066. doi: 10.3892/ijo.2017.4066 pmid: 28677801
[9]	Zhou X, Zhang CZ, Lu SX, et al. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma[J]. Oncogene, 2016,35(38):5078. DOI: 10.1038/onc.2016.61. pmid: 27477694
[10]	Jiang T, Li M, Li Q, et al. MicroRNA-98-5p inhibits cell proliferation and induces cell apoptosis in hepatocellular carcinoma via targeting IGF2BP1[J]. Oncol Res, 2017,25(7):1117-1127. DOI: 10.3727/096504016X14821952695683. doi: 10.3727/096504016X14821952695683 pmid: 28244848
[11]	Fawzy IO, Hamza MT, Hosny KA, et al. miR-1275: a single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma[J]. FEBS Lett, 2015,589(17):2257-2265. DOI: 10.1016/j.febslet.2015.06.038. doi: 10.1016/j.febslet.2015.06.038 pmid: 26160756
[12]	Rebucci M, Sermeus A, Leonard E, et al. miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1[J]. Mol Cancer, 2015,14:79. DOI: 10.1186/s12943-015-0349-6. pmid: 25889892

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

IGF2BP1与肿瘤

IGF2BP1 and cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 12

相关文章 15

编辑推荐

Metrics

本文评价